Moderna

Moderna's seasonal flu vaccine mRNA-1010 demonstrated 26.6% relative vaccine efficacy compared to standard vaccines in adults aged 50 and above, meeting prespecified superiority criteria.

Moderna presented new data on mRNA-4359, which is rapidly advancing to become one of the company's newest late-stage oncology assets.

A comprehensive French study of over 527,000 infants found no increased risk of major congenital malformations among babies exposed to mRNA COVID-19 vaccines during the first trimester of pregnancy.

Researchers at JABSOM have developed an mRNA-based nanobody therapy that blocks PD-L1 and reduced colorectal cancer tumor growth by 50% in mouse models.

Shah Capital, Novavax's second-largest shareholder with a 7.2% stake, has urged the company's board to pursue a sale, citing three consecutive years of poor COVID-19 vaccine performance.

A large study of nearly 300,000 U.S. military veterans found that 2024-2025 COVID-19 mRNA boosters reduced emergency department visits by 29%, hospitalizations by 39%, and deaths by 64% compared to unvaccinated individuals.

Monash University has established the Monash Boston Hub in Cambridge to deepen collaborations with North American and European biotech companies for drug discovery and health innovations.

Moderna's Innovation and Technology Centre in Harwell, Oxfordshire is now operational as the UK's first facility to manufacture mRNA vaccines onshore, capable of producing up to 100 million doses annually.

Australia's first fully integrated mRNA vaccine facility by Moderna could save the nation $4.8 billion during pandemics over the next 30 years, according to an Oxford Economics report.

Moderna has settled patent infringement lawsuits filed by Alnylam Pharmaceuticals over alleged misuse of lipid nanoparticle technology in COVID-19 vaccines.